Atrium Therapeutics has reported Q2 2026 earnings alongside FDA IND clearance for ATR 1072 and the launch of its first clinical trial, Corventis, in PRKAG2 syndrome.
#Biotech #ClinicalTrials #FDA #DrugDevelopment #RareDisease
Disclaimer: This is NOT a financial advice
Atrium Therapeutics has reported Q2 2026 earnings alongside FDA IND clearance for ATR 1072 and the launch of its first clinical trial, Corventis, in PRKAG2 syndrome. #Biotech #ClinicalTrials #FDA #DrugDevelopment #RareDisease Disclaimer: This is NOT a financial advice
0 views
Published on 18/08/2026 07:52
Atrium Therapeutics has reported Q2 2026 earnings alongside FDA IND clearance for ATR 1072 and the launch of its first clinical trial, Corventis, in PRKAG2 syndrome.
#Biotech #ClinicalTrials #FDA #DrugDevelopment #RareDisease
Disclaimer: This is NOT a financial advice
0 comments
?